What You Should Know:
– Gilead Sciences, a global biopharmaceutical company, and Genesis Therapeutics, an AI-focused biotechnology firm, have announced a strategic collaboration to discover and develop innovative small molecule therapies.
– The startegic partnership leverages Genesis’ cutting-edge AI platform, GEMS, to accelerate drug discovery and development.
A Powerful Collaboration
Genesis Therapeutics’ GEMS platform utilizes advanced AI techniques to generate and optimize molecules for challenging targets. By combining Gilead’s expertise in drug development with Genesis’ AI capabilities, the collaboration aims to identify novel therapeutic candidates for a range of diseases.
Key Terms of the Agreement
- Upfront Payment: Genesis will receive an upfront cash payment of $35 million.
- Target Options: Gilead has the option to nominate additional targets for a fee.
- Milestone Payments: Genesis is eligible for preclinical, development, regulatory, and commercial milestone payments.
- Royalties: Genesis will receive tiered royalties on net sales of any commercialized products.
Financial Impact
The transaction with Genesis is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.02.
“The use of generative AI in drug development, enabled by people, science and other new technology, has shown potential to accelerate the discovery of molecules for challenging targets,” said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. “We look forward to working with Genesis to apply their AI platform to discover and advance novel therapies that may address significant unmet patient needs.”
